Aptose Biosciences and Hanmi Pharmaceutical to Collaborate
Aptose Biosciences Inc. (TSX: APS; OTC: APTOF) and Hanmi Pharmaceutical Co. Ltd. have recently engaged in a significant arrangement agreement for the potential acquisition of Aptose. The arrangement allows Hanmi, through its subsidiary HS North America Ltd., to acquire all the outstanding common shares of Aptose that are not already owned by them or their affiliates.
Details of the Acquisition Agreement
Hanmi has been a notable supporter of Aptose, holding almost 20% of its shares and providing financial backing exceeding USD 30 million over the past year and a half. The acquisition deal guarantees that Aptose shareholders, aside from those affiliated with Hanmi, will receive C$2.41 in cash per share—a 28% premium on Aptose's average stock price over the previous month.
Continuous Development of Tuspetinib
The CEO of Aptose, William G. Rice, expressed enthusiasm regarding this agreement. He highlighted how the transaction secures a favorable return for current shareholders while allowing ongoing development of tuspetinib, a key focus for Aptose, particularly regarding therapeutic approaches for acute myeloid leukemia (AML). The triplet therapy combining tuspetinib with venetoclax and azacitidine has exhibited promising results in clinical trials, providing hope for patients diagnosed with AML.
Expansion into North America
Hanmi’s Jae-Hyun Park remarked on the importance of this transaction. With a growing repository of positive clinical data, the acquisition facilitates Hanmi's entry into the North American market, paving the way for future strategic partnerships and potential expansions in the region.
Transaction Mechanics and Conditions
A significant aspect of the arrangement involves transitioning Aptose from its current corporate structure under the Canada Business Corporations Act to one governed by the Business Corporations Act (Alberta). Effective upon completion of the arrangement, shareholders can expect cash payments for their shares, alongside adjustments for options and warrants held.
Special Meeting and Shareholder Approval
To finalize the agreement, certain conditions must be fulfilled, including court approvals and a special meeting of Aptose shareholders to be held no later than January 16, 2026. During this meeting, a two-thirds majority is required to approve the continuation of the acquisition.
Valuation and Recommendations
The Special Committee consulted with Locust Walk Securities, which provided a formal valuation deeming the offer of C$2.41 per share fair from a financial perspective. This validation comes after extensive analysis and several valuation methodologies, providing reassurance to stakeholders that the transaction aligns with Aptose's long-term goals.
Endorsement from the Board
Aptose’s Board unanimously endorsed the acquisition proposal, advising shareholders to vote in favor of the arrangement. Their endorsement signifies strong internal support for this strategic move that aims to bolster Aptose’s standing in the biotechnology field.
Advisors and Further Insights
Locust Walk is advising the Special Committee, while McCarthy Tétrault LLP provides legal counsel to both Aptose and the Special Committee. This alignment of expert guidance amplifies the acquisition's integrity and alignment with industry standards.
About the Lead Product: Tuspetinib
Tuspetinib, Aptose’s core product, is an oral agent with a unique capacity to combat several forms of cancer while minimizing typical side effects associated with treatment. The ongoing TUSCANY study aims to determine optimal dosing strategies in combination with other established therapeutics, with initial results showcasing encouraging remission rates across various patient demographics.
About the Companies
Founded in 1973 in South Korea, Hanmi Pharmaceutical has established itself as a leader in the global biopharmaceutical space, working towards innovative treatments in key therapeutic areas. Concurrently, Aptose focuses on advanced oncology solutions, particularly in aiding patients with complex blood cancers. Their lead candidate, tuspetinib, is designed to meet unaddressed needs within the oncology landscape.
Frequently Asked Questions
What is the nature of the deal between Aptose and Hanmi?
Hanmi will acquire all outstanding common shares of Aptose that are not already owned by them or their affiliates, providing a premium cash offer to shareholders.
What is tuspetinib and its relevance in this agreement?
Tuspetinib is Aptose's lead compound targeting multiple cancer-causing mutations while minimizing toxicity, and its development is prioritized in this acquisition.
How will shareholders benefit from this acquisition?
Shareholders are set to receive a cash payment of C$2.41 per share, representing an attractive premium compared to prior market values.
What steps remain for the acquisition to proceed?
The acquisition requires court approval and satisfactory shareholder votes, which will occur at a special meeting by January 16, 2026.
What role does Locust Walk play in this transaction?
Locust Walk provides financial advice and valuation services to ensure the deal is in the best interests of Aptose shareholders, enhancing the transaction's credibility.
